Gemcitabine and paclitaxel suppress the production of vascular endothelial growth factor induced by deferoxamine in human non-small cell lung cancer A549 cells

RYUJI IKEDA1, LEE C. VERMEULEN2, ZHISHENG JIANG3, ELIM LAU3 and JILL M. KOLESAR3

1Department of Clinical Pharmacy and Pharmacology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan; 2Division of Pharmacy Practice, School of Pharmacy, University of Wisconsin-Madison and Center for Drug Policy, University of Wisconsin Hospital and Clinics; 3School of Pharmacy, University of Wisconsin, and University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison, WI, USA

Received May 27, 2010; Accepted July 19, 2010
DOI: 10.3892/etm.2010.130

Abstract. Vascular endothelial growth factor (VEGF) plays an important role in the process of angiogenesis in many types of cancer, including non-small cell lung cancer (NSCLC), and angiogenesis inhibitors and standard chemotherapy exhibit synergy though an unknown mechanism. We therefore hypothesized that cytotoxic chemotherapy influences VEGF production and analyzed VEGF production in an NSCLC A549 cell line after treatment with standard chemotherapy. Paclitaxel inhibited the production of VEGF in A549 cells, while cisplatin and erlotinib did not. Paclitaxel and gemcitabine inhibited deferoxamine (DFX) (known to mimic hypoxia)-induced VEGF production in A549 cells. Erlotinib also inhibited DFX-induced VEGF production in A549 cells slightly, while cisplatin did not. We subsequently examined the effect of the interaction between paclitaxel or gemcitabine and VEGF protein. Paclitaxel and gemcitabine did not directly affect the binding of VEGF. Since VEGF is known as one of the HIF-1 target genes, we examined the effect of paclitaxel and gemcitabine on HIF-1α levels induced by DFX in A549 cells. Paclitaxel and gemcitabine inhibited DFX-induced HIF-1α in A549 cells. These findings may be useful for future treatment schedules, including anti-cancer agents in NSCLC.

Introduction

Lung cancer is the leading cause of cancer-related death in developed nations. In the US, an estimated 219,440 new cases and 159,390 deaths were projected for 2009 (1,2). Non-small cell lung cancer (NSCLC) commonly presents as incurable locally advanced or metastatic disease. Despite major research efforts, survival prospects remain dismal small, and 14% of all patients with lung cancer are expected to live 5 years after diagnosis (3). Recent innovations to improve treatment for NSCLC have focused on targeted inhibitors, including the vascular endothelial growth factor (VEGF) inhibitor bevacizumab. Angiogenesis is a critical component for growth and the metastatic spread of tumors (4). Mediators of angiogenesis include VEGF, which is overexpressed in many malignancies, NSCLC among them. Expression of VEGF in tumor or serum has been linked to poor survival outcomes and response to therapy (1,5-9). In patients with advanced incurable NSCLC, cisplatin-based combinations have resulted in improved survival rates. Moreover, platinum combined with anti-cancer agents, such as paclitaxel, docetaxel, gemcitabine, vinorelbine or pemetrexed (3), in combination with bevacizumab, in bevacizumab-eligible patients, is recommended as first-line therapy for most patients (3). Both in vivo (10) and in vitro (11,12) evaluations have demonstrated synergy between the VEGF inhibitor bevacizumab and cytotoxic chemotherapy, although the mechanism is unknown. Hanrahen et al recently demonstrated that the combination of paclitaxel and carboplatin decreased VEGF in vivo (13).

We hypothesized that bevacizumab chemotherapy synergy may result from the inhibition of VEGF. We therefore examined whether cisplatin, erlotinib, paclitaxel and gemcitabine affect the production of VEGF in NSCLC A549 cells.

Materials and methods

Reagents. A human VEGF immunoassay was obtained from R&D Systems, Inc. (Minneapolis, MN, USA). Paclitaxel, deferoxamine and 3-[4,5-dimethyl-thiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) were obtained from Sigma Chemical Co. (St. Louis, MO, USA). Gemcitabine hydrochloride was from LKT Laboratories, Inc. (St. Paul, MN, USA). Erlotinib was from Chemie Tek (Indianapolis, IN, USA). Fetal bovine serum (FBS), Dulbecco's modified Eagle's medium...
iKeda et al. GEmcitaBinE and paclitaxEl rEprESS thE prOductiOn OF VEGF

854

(DMEM), penicillin-streptomycin solution (10,000 U/ml penicillin and 10,000 µg/ml streptomycin) were from Hyclone (Logan, UT, USA). Antibody against HIF-1α was from BD Biosciences (San Jose, CA, USA).

Cell culture. The A549 cell line, derived from NSCLC, was maintained in DMEM containing 10% FBS, 100 U/ml penicillin and 100 µg/ml streptomycin at 37°C in a 5% CO₂ humidified atmosphere.

Cell proliferation by 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) assay. Cell proliferation in vitro was measured by the MTT colorimetric assay in 96-well plates. The cells (5x10³) were inoculated into each well. After overnight incubation (37°C in 5% CO₂), anti-cancer agents were added to the culture and were then incubated for 24 h. Thereafter, 50 µl of MTT (1 mg/ml) was added to each well, and the plates were incubated for an additional 4 h. After aspiration of the culture medium, the resulting formazan was dissolved with 100 µl of dimethylsulfoxide. The plates were read at 570 nm using a microplate reader.

Binding analysis of the effect of paclitaxel and gemcitabine on VEGF. To examine the effect of paclitaxel or gemcitabine on the binding of VEGF, 100 µl of VEGF (250 pg/ml) was mixed with 100 µl of paclitaxel (final concentrations: 1, 10 and 100 µM) or gemcitabine (final concentrations: 1, 10 and 100 µM). After 1-h reaction periods, the concentrations of VEGF were detected with ELISA according to the manufacturer's guidelines.

Measurement of VEGF in conditioned media. The cells were plated in 96-well plates at 1x10⁴ cells/well and cultured overnight. The growth medium was replaced with serum-free medium. These cells were routinely maintained at 37°C in a humidified atmosphere of 5% CO₂ for an additional 24 h.

Protein extraction and immunoblotting. The cells were harvested and lysed with RIPA buffer [50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 1% Nonidet P-40, 0.1% SDS, 0.5% sodium deoxycholate, 1 mM p-amidinophenyl methanesulfonyl fluoride hydrochloride and 1 µg/ml aprotinin. Samples were subjected to 6% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) according to the method of Laemmli. Proteins were electrophoretically transferred onto polyvinylidene difluoride membranes (Immobilon-P transfer membrane; Millipore, Bedford, MA, USA) using Bio-Rad Transblot SD apparatus. The membrane was treated with buffer A [350 mM NaCl, 10 mM Tris-HCl (pH 8.0) and 0.05% Tween-20] containing 3% skimmed milk for 1 h and incubated with the indicated antibody (1:1,000) in buffer A containing 3% skimmed milk for 1 h. Following four washes with buffer A (10 min each), the membrane was incubated with a peroxidase-conjugated horse anti-mouse IgG diluted 1:1,000 in buffer A containing 3% skimmed milk for 1 h. The membrane was washed with buffer A and developed using an enhanced chemiluminescence Western blotting detection system (Amersham Biosciences, Buckinghamshire, UK).

Statistical analysis. Differences between groups were tested by one-way ANOVA. Data are presented as the means ± SD. Differences were considered significant at P<0.05.

Results

Effect of anti-cancer agents on VEGF production in A549 cells. To investigate the effect of anti-cancer agents on the production of VEGF, A549 cells were treated with cisplatin, erlotinib, paclitaxel or gemcitabine for 24 h, followed by ELISA analysis for VEGF. As shown in Fig. 1A, paclitaxel was capable of reducing the production of VEGF, while cisplatin and erlotinib did not affect production. Gemcitabine slightly suppressed the production of VEGF.

Effect of anti-cancer agents on A549 cell proliferation. To examine the effect of anti-cancer agents on the cell proliferation of A549 cells, we performed the MTT assay. A549 cells were cultured in DMEM media to eliminate the exogenous source of growth factors. As shown in Fig. 1B, cisplatin and erlotinib had no effect on A549 cell proliferation. Whereas paclitaxel inhibited cell proliferation, gemcitabine was less effective than paclitaxel (P<0.05).
Effect of anti-cancer agents on VEGF production in A549 cells in the presence of deferoxamine. Expression of VEGF is up-regulated by hypoxic conditions in tumor cells and by the activation of oncogenes such as v-Src and Ras (14-16). To examine the effect of a hypoxic condition on the production of VEGF, A549 cells were exposed to deferoxamine (DFX). DFX is known as a hypoxia mimic agent and an iron chelator that depletes iron and inhibits oxygen, Fe$^{2+}$ and oxoglutarate-dependent dioxygenases (17). As shown in Fig. 2A, VEGF production levels were increased by DFX after 24 h in A549 cells. The cells treated with cisplatin did not affect VEGF production. Paclitaxel and gemcitabine suppressed the production of VEGF, although erlotinib was less effective than paclitaxel and gemcitabine (P<0.05).

Effect of anti-cancer agents on A549 cell proliferation in the presence of deferoxamine. To investigate the effect of anti-cancer agents on the proliferation of A549 cells in the presence of DFX, an MTT assay was performed. As shown in Fig. 2B, cell proliferation was inhibited by DFX, while the cells treated with DFX and chemotherapy were not inhibited to a greater extent than those treated with DFX alone. These results suggest that the inhibitory effect of paclitaxel and gemcitabine on VEGF production was independent of the proliferation of A549 cells.

Effect of paclitaxel and gemcitabine on the binding of VEGF. To investigate whether paclitaxel and gemcitabine interact with VEGF, 100 µl of VEGF (250 ng/ml) was mixed with 100 µl of paclitaxel (final concentrations: 1, 10 and 100 µM) or gemcitabine (final concentrations: 1, 10 and 100 µM). Subsequently, the concentrations of VEGF were detected with ELISA. As shown in Fig. 3, paclitaxel and gemcitabine did not directly affect the binding of VEGF.

Effect of paclitaxel and gemcitabine on HIF-1α expression induced by deferoxamine in A549 cells. VEGF is known as one of the HIF-1 target genes (18). We therefore determined the effect of paclitaxel or gemcitabine on the protein level of HIF-1α induced by DFX in A549 cells. As shown in Fig. 4,
the incubation of A549 cells in the presence of DXF resulted in a marked increase in HIF-1α protein levels. Treatment with paclitaxel and gemcitabine substantially suppressed the induction of HIF-1α in A549 cells in the presence of DXF.

Discussion

VEGF is a potent inducer of angiogenesis both in vivo and in vitro (19-21). Mutations of one or both alleles of the VEGF gene result in an embryonic lethal phenotype in mice due to inadequate vascularization, suggesting that VEGF is required for the early stages of vascular development (22,23). Expression of VEGF is up-regulated in a variety of human tumors, including lung cancer, and VEGF-stimulated angiogenesis seems to be required for the development of solid tumors (24,25). The inhibition of VEGF expression was in turn found to inhibit tumor angiogenesis in vivo and decrease tumor size in nude mice (26-28). VEGF has also been frequently evaluated in clinical trials of angiogenesis inhibitors and is accepted as a marker of drug activity. In this study, we demonstrated that gemcitabine and paclitaxel inhibited the production of VEGF in NSCLC A549 cells. This suggests that cytotoxic chemotherapy also reduces VEGF production, and that the inhibition of VEGF may be a mechanism by which synergy occurs between cytotoxic chemotherapy and angiogenesis inhibitors.

Paclitaxel is known to induce mitotic arrest and apoptosis by inhibiting the depolymerization of microtubules. Tumor growth and metastasis are affected by the metabolic rate and angiogenesis. Loo et al also reported that paclitaxel is an effective cytotoxic agent with possible anti-angiogenic effects (29).

Gemcitabine, a chemotherapeutic agent used in the treatment of advanced NSCLC, is an analogue of deoxycytidine and is phosphorylated to 5'-monophosphate by deoxycytidine kinase. It is then phosphorylated by uridylate-cytidylate monophosphate kinase to difluorodeoxycytidine 5-diphosphate, which interferes with the function of ribonucleotide reductase and reduces the pool of deoxyribonucleotide 5-phosphate available for DNA synthesis (30). Pre-treatment of transitional bladder cancer cell lines with VEGF antisense oligodeoxynucleotides may increase sensitivity to chemotherapy. Combination treatment with VEGF antisense oligodeoxynucleotides and anti-cancer agents, such as mitomycin C, gemcitabine or cisplatin, was found to decrease the cell viability compared to nonsense oligodeoxynucleotide plus anti-cancer agents (31,32). These results suggest that VEGF is an additional putative target for enhancing therapeutic benefit. The inhibition of VEGF by gemcitabine and paclitaxel also has novel potential use in anti-cancer drug therapy, and represents a novel method for inhibiting tumor angiogenesis in NSCLC tumorigenesis.

VEGF is known as one of the HIF-1 target genes, and HIF-1α is rapidly degraded in normoxia by the ubiquitin proteasome pathway (18,33). Polyubiquitination of HIF-1α is mediated by the von Hippel-Lindau tumor suppressor (VHL), and VHL binding is controlled by hydroxylation of two proline residues (Pro-402 and Pro-564) in HIF-1α. These prolines are modified in normoxia by HIF prolyl-4-hydroxylase, which requires oxygen, iron and 2-oxoglutarate as co-factors. Depletion of oxygen or iron chelation inhibits enzyme activity, resulting in the stabilization of HIF-1α (33). Further study is required to elucidate the mechanism of the inhibitory effect of gemcitabine and paclitaxel on HIF-1α levels in NSCLC A549 cells.

In conclusion, our results demonstrate that paclitaxel and gemcitabine modulate angiogenesis by decreasing VEGF, even under conditions of hypoxia. These agents will aid in the design of future chemotherapy protocols for NSCLC patients.

Acknowledgements

At the time this research was conducted, Dr Ikeda was a visiting scholar at the School of Pharmacy, University of Wisconsin-Madison, and the University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison, WI, USA.

References


